IBSA Pharma
Turnover is estimated at about €1.2m, probably between €910,000 and €1.7m.
Balance sheet
balance sheet total €71,733 on 31-12-2025in euro
in euro
Position in the sector
48.6%
Higher than 55% of the 3,805 companies filing full accounts in wholesale trade (NACE 46) in 2025.
1.95
Higher than 58% of the 3,771 companies filing full accounts in wholesale trade (NACE 46) in 2025.
1.8%
Higher than 36% of the 3,803 companies filing full accounts in wholesale trade (NACE 46) in 2025.
Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: bottom quarter · Staff: bottom quarter
Staff
€116,709
Staff costs divided by the average number of full-time equivalents.
level
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| -11,057 | 16,394 | - | ||
| 34,853 | 33,554 | 27,438 | ||
| 48.6% | 37.0% | 31.4% | ||
| 1.95 | 1.59 | 1.46 | ||
| 1.06 | 1.71 | 2.18 | ||
| 3.7% | 18.2% | 8.9% | ||
| 1.8% | 6.7% | 2.8% |
EBIT margin not included in this filing.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
71,733 | 90,799 | 87,334 | |
29/58 |
71,733 | 90,799 | 87,334 | |
40/41 |
49,588 | 56,953 | 71,927 | |
40 |
48,005 | 43,900 | 66,750 | |
41 |
1,583 | 13,053 | 5,177 | |
54/58 |
20,597 | 31,653 | 15,259 | |
490/1 |
1,548 | 2,193 | 148 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
71,733 | 90,799 | 87,334 | |
10/15 |
34,853 | 33,554 | 27,438 | |
10/11 |
25,000 | 25,000 | 25,000 | |
14 |
9,853 | 8,554 | 2,438 | |
17/49 |
36,880 | 57,245 | 59,896 | |
42/48 |
36,880 | 57,245 | 59,896 | |
44 |
6,482 | 9,939 | 31,854 | |
440/4 |
6,482 | 9,939 | 31,854 | |
45 |
30,398 | 47,306 | 28,042 | |
450/3 |
15,802 | 24,674 | 16,803 | |
454/9 |
14,596 | 22,633 | 11,239 | |
| Income statement | ||||
9900 |
252,632 | 317,984 | 100,159 | |
62 |
233,418 | 296,979 | 91,752 | |
640/8 |
465 | - | - | |
9901 |
18,750 | 21,006 | 8,407 | |
75/76B |
0 | 1 | - | |
75 |
0 | 1 | - | |
65/66B |
6,759 | 7,016 | 1,794 | |
65 |
6,759 | 7,016 | 1,794 | |
9903 |
11,991 | 13,990 | 6,612 | |
67/77 |
10,692 | 7,875 | 4,174 | |
9904 |
1,299 | 6,116 | 2,438 | |
9905 |
1,299 | 6,116 | 2,438 | |
| Appropriation of the result | ||||
9906 |
9,853 | 8,554 | 2,438 | |
14P |
8,554 | 2,438 | - | |
| Social balance sheet | ||||
9087 |
2 | 2 | 2 | |
Hours worked1013 |
2,932 | 3,212 | 1,784 | |
| Document | ||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 19-05-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankSocial balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 |
|---|---|---|---|
| Employees at the balance-sheet date | 2 | 2 | 2 |
| full-time | 2 | 2 | 2 |
| part-time | 0 | 0 | 0 |
| in full-time equivalents | 2 | 2 | 2 |
| 2 | 2 | 2 | |
| On a permanent contract | 2 | 1 | 2 |
| Joined | 1 | 1 | 2 |
| Left | 1 | 1 | 0 |
Source: social balance sheet in the 2023 to 2025 annual accounts
Insights on IBSA Pharma
The operating result for 2025 is 11% lower than in 2024.
Debt's share of the balance-sheet total falls from 63.0% to 51.4%. Equity is higher and debt is lower.